Back
Halozyme Therapeutics Stock Price Chart
AI Is Disrupting Marketing—Invest Before April 10!
⏳ Secure Your Stake in AI Marketing Before This Window Closes!
Buy
77
HALO
Halozyme Therapeutics
Last Price:
$61.84
Seasonality Move:
3.37%
7 Day Trial
ALL ACCESS PASS
$
7
Final Days: Should You Invest in This AI Startup Now?
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering. Please read the offering circular and related risks at invest.radintel.ai.-
The current trend is moderately bearish and HALO is experiencing buying pressure, which is a positive indicator for future bullish movement.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 64.29 | Sell |
| 20-day SMA: | 62.32 | Buy |
| 50-day SMA: | 59.07 | Buy |
| 200-day SMA: | 55.14 | Buy |
| 8-day EMA: | 63.86 | Sell |
| 20-day EMA: | 62.46 | Buy |
| 50-day EMA: | 59.37 | Buy |
| 200-day EMA: | 53.77 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.72 | Buy |
| Relative Strength Index (14 RSI): | 62.31 | Buy |
| Chaikin Money Flow: | 1060952 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (58.91 - 64.05) | Buy |
| Bollinger Bands (100): | (48.91 - 60.67) | Buy |
Halozyme Therapeutics Technical Analysis
| Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 28 | Mar 31 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | ||||||||||
| 18 | 19 | 20 | 21 | 24 | 25 | 26 | 27 | 28 | 31 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 63.81 while HALO 8-day simple moving average is 64.29, which is a Sell signal.
-
The stock price of HALO is 63.81 while Halozyme Therapeutics 20-day SMA is 62.32, which makes it a Buy.
-
Halozyme Therapeutics 50-day simple moving average is 59.07 while HALO share price is 63.81, making it a Buy technically.
-
HALO stock price is 63.81 and Halozyme Therapeutics 200-day simple moving average is 55.14, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
77
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a BuyThe current Halozyme Therapeutics [HALO] share price is $63.81. The Score for HALO is 77, which is 54% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.9B
Price in USD:
63.81
Share Volume:
1.6M
Halozyme Therapeutics 52-Week Range
52-Week High:
66.00
52-Week Low:
37.73
Buy
77
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?The Halozyme Therapeutics stock price is 63.81 USD today.
-
Will HALO stock go up or go down?Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Halozyme Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 63.81 while HALO 8-day exponential moving average is 63.86, which is a Sell signal.
-
The stock price of HALO is 63.81 while Halozyme Therapeutics 20-day EMA is 62.46, which makes it a Buy.
-
Halozyme Therapeutics 50-day exponential moving average is 59.37 while HALO share price is 63.81, making it a Buy technically.
-
HALO stock price is 63.81 and Halozyme Therapeutics 200-day simple moving average is 53.77, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.33 per share, an increase next quarter of $0.02 per share, an increase this year of $0.77 per share, and an increase next year of $1.51 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
-
HALO Moving Average Covergence Divergence (MACD) indicator is 1.72, suggesting Halozyme Therapeutics is a Buy
-
Halozyme Therapeutics Relative Strength Index (RSI) is 62.31, which suggest Halozyme Therapeutics is overbought
-
The Bollinger Bands (25) for Halozyme Therapeutics is (58.91 - 64.05), which suggest Halozyme Therapeutics is a Buy
-
The Bollinger Bands (100) for Halozyme Therapeutics is (48.91 - 60.67), which suggest Halozyme Therapeutics is a Buy
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.